Premium
Beneficial Effects of Short‐Term Lamivudine Treatment for de novo Hepatitis B Virus Reactivation After Liver Transplantation
Author(s) -
Umeda M.,
Marusawa H.,
Ueda M.,
Takada Y.,
Egawa H.,
Uemoto S.,
Chiba T.
Publication year - 2006
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2006.01542.x
Subject(s) - lamivudine , medicine , hbsag , hepatitis b virus , liver transplantation , transplantation , hepatitis b , virology , gastroenterology , immunology , virus
Clearance of hepatitis B surface antigen (HBsAg) by lamivudine is achieved in only a small proportion of patients with chronic hepatitis B virus (HBV) infection. We investigated the effect of lamivudine on de novo HBV reactivation after living‐donor liver transplantation when the number of HBV was expected to be very small. Thirty‐eight HBV‐naive recipients who received liver grafts from antibodies to core antigen‐positive donors receiving hepatitis B immunoglobulin (HBIG) were studied. HBsAg appeared in nine cases (23.7 %) despite receiving HBIG for 12–71 months (mean: 35.1 months) after transplantation. Lamivudine treatment was started in six recipients during the acute phase of HBV reactivation. Five of the six recipients achieved complete clearance of HBsAg in sera at a median of 4.6 months (ranging from 21 to 330 days) after lamivudine administration. Although lamivudine was stopped in four cases, all remained negative for HBsAg. Our findings suggested that short‐term lamivudine treatment during acute phase of HBV reactivation could achieve complete clearance of HBsAg in a significant number of liver transplant recipients.